Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ataciguat (HMR1766), HMR1766
Ataciguat · 3 trials · 3 indications
The primary objective of the current study is to determine whether Ataciguat (HMR1766) is well-tolerated by patients with moderate calcific aortic valve stenosis. In this particular patient population, incidence of orthostatic intolerance/symptomatic hypotension is a potential concern.
The primary objective of the current study is to determine whether Ataciguat (HMR1766) is well-tolerated by patients with moderate calcific aortic valve stenosis. In this particular patient population, incidence of orthostatic intolerance/symptomatic hypotension is a potential concern. Transitioning from sitting to standing is a functional test that will allow us to examine the effects of Ataciguat on blood pressure regulation in response to a relevant orthostatic stress.
The primary objective of the current study is to determine whether Ataciguat (HMR1766) is well-tolerated by patients with moderate calcific aortic valve stenosis. In this particular patient population, incidence of orthostatic intolerance/symptomatic hypotension is a potential concern. Tilt table testing will allow us to examine the effects of Ataciguat on blood pressure regulation in response to a tightly controlled orthostatic stress.
The primary objective of the current study is to determine whether Ataciguat (HMR1766) is well-tolerated by patients with moderate calcific aortic valve stenosis. In this particular patient population, incidence of orthostatic intolerance/symptomatic hypotension is a potential concern. Evaluating subject perceptions of light-headedness/orthostatic intolerance will help us to understand the relationship between changes in blood pressure and changes in symptoms in this patient population before and after treatment with Ataciguat.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | First period: Ataciguat - Second period: Placebo |
| 2 | EXPERIMENTAL | First period: Placebo - Second period: Ataciguat |
| 3 | EXPERIMENTAL | dose level 2 |
| 4 | EXPERIMENTAL | dose level 3 |
| 5 | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | Placebo gel capsule, dosage matches number of Ataciguat capsules for each respective dose, capsules taken once daily with breakfast for 14 consecutive days. |
| Ataciguat | ACTIVE_COMPARATOR | Ataciguat, orally administered gel capsule, 50, 100, or 200 mg, once per day with breakfast for 14 consecutive days |
| Name | Type | Description |
|---|---|---|
| ataciguat (HMR1766) | DRUG | oral administration 200mg once daily for 28 days |
| placebo | DRUG | oral administration once daily for 28 days |
| cilostazol | DRUG | oral administration |
| Ataciguat | DRUG | - |
Inclusion Criteria: * Patients with chronic neuropathic pain due to diabetic polyneuropathy or a nerve lesion following surgery. The pain must be present for more than 3 months. Exclusion Criteria: * Presence or history of cancer within the past five years * Patients with a history of HIV infecti...
Ataciguat has been studied in aortic valve stenosis, intermittent claudication, and pain. It is an investigational small molecule developed by Sanofi (ticker: SNY) and has not been approved for any indication. Clinical research has explored its use in cardiovascular and pain conditions.
Ataciguat targets the soluble guanylate cyclase subunits GUCY1B1, GUCY1A2, and GUCY1A1. It acts as an activator of these enzymes, which are involved in the nitric oxide signaling pathway that regulates vascular tone and blood flow.
Ataciguat is being developed by Sanofi, a global pharmaceutical company traded under the ticker SNY. Sanofi has sponsored clinical trials of ataciguat in cardiovascular and pain indications.
Ataciguat is in Phase 1 of clinical development. It is an investigational drug and has not received FDA approval. The Phase 1 trial focused on safety in patients with moderate calcific aortic valve stenosis.
Ataciguat has been evaluated in three completed clinical trials: NCT02049203 in aortic valve stenosis, NCT00799656 in neuropathic pain, and NCT00443287 in intermittent claudication. All trials are completed, and no active trials are currently listed.
Yes, ataciguat is also known as HMR1766. HMR1766 was the early development code used by Sanofi, and the compound is now referred to as ataciguat in scientific literature and clinical trial records.